Related Experiment Video
Updated: Sep 13, 2025
Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16
Published on: July 15, 2019
Dehydrotumulosic acid: a potential glucocorticoid receptor agonist with anti-coxsackievirus activity
Jieyu Li1, Yuanyuan Huang1, Qiting Luo2
1School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, PR China; College of Pharmacy, Shenzhen Technology University, Shenzhen, 518118, PR China.
Background:
Coxsackievirus infections cause a range of diseases, from hand-foot-and-mouth disease to severe conditions such as myocarditis and meningoencephalitis. High mutation rates and serotype diversity complicate clinical management, as no approved vaccines or therapies exist. Triterpenoids, natural compounds with antiviral and immunomodulatory effects, offer potential as novel treatments.
Purpose:
This study evaluated the antiviral potential of dehydrotumulosic acid (DA), a triterpenoid derived from Poria cocos, against coxsackievirus B3 (CVB3) and other serotypes, while exploring its mechanism of action.
Methods:
The antiviral activity of DA was tested in vitro across multiple coxsackievirus serotypes using cytopathic effect inhibition, qRT-PCR(quantitative Reverse Transcription Polymerase Chain Reaction), Western blotting, and plaque assays to measure viral replication, mRNA, and protein levels. Transcriptomic profiling and cellular thermal shift assays provided mechanistic insights.
Results:
DA exhibited strong antiviral effects against coxsackievirus B1 (CVB1), coxsackievirus B2 (CVB2), CVB3, coxsackievirus A16 (CVA16), and coxsackievirus A (CVA6), reducing viral replication, mRNA, and protein synthesis in a dose-dependent manner without cytotoxicity. Mechanistically, DA binds and activates the glucocorticoid receptor (GR), suppressing MAPK (Mitogen-Activated Protein Kinase) /ERK(Extracellular Signal-Regulated Kinase) signaling and proinflammatory cytokine production. Compared to dexamethasone, a known GR agonist, the effects of DA were more sustained, highlighting its dual antiviral and anti-inflammatory benefits.
Conclusion:
DA emerges as a promising host-targeted antiviral agent for coxsackievirus infections, addressing the critical unmet need for effective therapies. Its innovative dual action-combining potent antiviral activity with anti-inflammatory effects via GR activation-distinguishes it from existing approaches, offering a promising candidate for further development.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...